Abstract
Background Fabry disease (FD) is an X-linked disorder with progressive myocardial sphingolipid deposition, causing premature cardiovascular morbidity and mortality. Advanced electrocardiography (A-ECG) has the potential to predict cardiac involvement. Objectives To evaluate the predictive power of A-ECG in identifying: 1) early cardiac involvement defined as low myocardial T1 on cardiovascular magnetic resonance (CMR), 2) adverse cardiovascular outcomes, and 3) heart age. Methods In this longitudinal multi-centre study, patients underwent same-day CMR and digital ECG, analysed using in-house software, including conventional ECG, derived vectorcardiographic, and singular value decomposition measures of waveform complexity parameters. Significant A-ECG variables were identified using stepwise forward regression and incorporated in a multivariable logistic regression A-ECG score. A Youden index was applied to identify best threshold score and bootstrapping performed to calculate the area under the receiver operating characteristics curve (AUC), sensitivity, specificity, and 95% confidence intervals (CI). Results In 155 patients (40% male, age 46+/-14 years, 39% on enzyme replacement therapy), left ventricular mass was higher in males compared to females (106 vs. 59 g/m2, p<0.001), 80% had low native T1, and 51% (70/136) had late gadolinium enhancement. A-ECG heart age was higher than chronological age in all patients (57+/-20 vs. 46+/-14 years, p<0.001). The heart age gap was strongly associated with T1 lowering and progressive LVH. Multivariable A-ECG scores for detecting low T1 had an AUC [95%CI] of 0.82 [0.75-0.89], sensitivity 72 [55-95] %, and specificity 85 [66-71] %; any arrhythmia 0.89 [0.82-0.95], 82 [68-94] %, 88 [70-96] %; or atrial fibrillation 0.89 [0.80-0.96], 92 [77-100] %, 83 [76-92] %, respectively. No predictors of heart failure hospitalisation or mortality were found. Conclusion A-ECG analysis has good diagnostic performance for predicting low native T1 and the occurrence of arrhythmias in Fabry disease but not for heart failure hospitalisation or death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by an investigator-led industry grant from Sanofi-Genzyme. The authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given to this study by University Hospitals Birmingham Research Ethics Committee and Northern Sydney Local Health District Human Research Ethics Committee. Local ethics approval was obtained for the Fabry400 study (14/LO/1948) and the Health Regulation Authority in the UK waivers consent for the use of data historically collected as part of a clinical service where its inclusion in research is secondary.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
